Quest Diagnostics Incorporated DGX
NYSE · Healthcare · Medical - Diagnostics & Research
$258.28
Close on Fri, 20 Nov 2026 · market value $28.4B
What the price is betting on
Below its recordAt $258, the price assumes revenue grows about 1.9% a year for five years, from $11.8B to about $12.8B by FY2030. That is less than what analysts expect for the next two years and less than the company's own last three years.
Revenue growth a year. The price figure comes from a reverse DCF at a 7.5% discount rate.
Track it and Parra checks each report against the path, and tells you when revenue falls behind it.
Own more than DGX? Check up to 5 of your stocks at once, free, no account.
Both sides
Three stories, three values
Bear
$275
Base
$309
Bull
$347
Today $258
- Bear $275. Cash flow grows 3% a year for the next 5 years, slower than expected, then slows to long-run growth.
- Base $309. Cash flow grows 5% a year for the next 5 years, as analysts expect, then slows to long-run growth.
- Bull $347. Cash flow grows 7% a year for the next 5 years, faster than expected, then slows to long-run growth.
Stories set by rules from the company’s record.
Checkpoints
The revenue the price needs
- YearNeedsAnalysts expect
- FY2026$11.9B$12.1B, on the path
- FY2027$12.1B$12.6B, on the path
- FY2028$12.4B$13.2B, on the path
- FY2029$12.6B$13.9B, on the path
- FY2030$12.8B$11.6B, below the path
Each year's revenue at 1.9% growth from $11.8B in the 12 months to September 2026.
At a glance
Healthcare · Medical - Diagnostics & Research · listed on NYSE
- Revenue, FY2025
- $11B
- Growth, 3 years a year
- 9.4%
- Cash margin
- 12%
- Net debt
- $6.5B
- Shares, 3-year change
- −4.2%
- Dividend yield
- 1.2%
What other healthcare prices are betting on
Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.